全文获取类型
收费全文 | 1883篇 |
免费 | 112篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 35篇 |
妇产科学 | 40篇 |
基础医学 | 223篇 |
口腔科学 | 53篇 |
临床医学 | 141篇 |
内科学 | 442篇 |
皮肤病学 | 9篇 |
神经病学 | 350篇 |
特种医学 | 58篇 |
外科学 | 203篇 |
综合类 | 5篇 |
一般理论 | 1篇 |
预防医学 | 146篇 |
眼科学 | 9篇 |
药学 | 162篇 |
中国医学 | 15篇 |
肿瘤学 | 104篇 |
出版年
2023年 | 9篇 |
2022年 | 28篇 |
2021年 | 60篇 |
2020年 | 38篇 |
2019年 | 46篇 |
2018年 | 57篇 |
2017年 | 38篇 |
2016年 | 45篇 |
2015年 | 66篇 |
2014年 | 68篇 |
2013年 | 95篇 |
2012年 | 117篇 |
2011年 | 116篇 |
2010年 | 74篇 |
2009年 | 60篇 |
2008年 | 87篇 |
2007年 | 93篇 |
2006年 | 82篇 |
2005年 | 73篇 |
2004年 | 82篇 |
2003年 | 89篇 |
2002年 | 58篇 |
2001年 | 50篇 |
2000年 | 51篇 |
1999年 | 35篇 |
1998年 | 15篇 |
1997年 | 9篇 |
1996年 | 16篇 |
1995年 | 15篇 |
1994年 | 11篇 |
1993年 | 8篇 |
1992年 | 30篇 |
1991年 | 29篇 |
1990年 | 25篇 |
1989年 | 27篇 |
1988年 | 25篇 |
1987年 | 20篇 |
1986年 | 20篇 |
1985年 | 17篇 |
1984年 | 20篇 |
1983年 | 7篇 |
1982年 | 7篇 |
1981年 | 6篇 |
1979年 | 12篇 |
1978年 | 9篇 |
1977年 | 6篇 |
1976年 | 12篇 |
1975年 | 6篇 |
1973年 | 4篇 |
1969年 | 6篇 |
排序方式: 共有2001条查询结果,搜索用时 31 毫秒
51.
O'Kane PD Reebye V Ji Y Stratton P Jackson G Ferro A 《Journal of molecular and cellular cardiology》2008,45(2):223-229
Aspirin and clopidogrel are used therapeutically for their anti-platelet effects. We examined the effects of aspirin and clopidogrel on basal and β-adrenoceptor (β-AR)-mediated platelet nitric oxide (NO) synthesis in healthy subjects and patients with coronary heart disease (CHD). Healthy subjects (n = 19) were randomized in a double-blind cross-over manner to receive aspirin or clopidogrel, each at 75 mg daily, for 14 days. Patients (n = 17) of similar age with CHD, taking aspirin, were randomized double-blind to either continue on aspirin 75 mg daily or to receive clopidogrel 75 mg daily for 14 days. NO synthase (NOS) activity was measured from l-[3H]arginine to l-[3H]citrulline conversion, and cGMP was determined by radioimmunoassay, in platelets basally and following incubation with isoproterenol or albuterol (each at 10−5 mol/L). In healthy subjects, aspirin did not affect basal NOS activity or cGMP in platelets, but suppressed the normal increase in both by isoproterenol and albuterol. Clopidogrel suppressed platelet NOS activity and cGMP both basally and in response to β-AR agonists. In platelets from CHD patients, clopidogrel suppressed basal and β-AR-stimulated NOS activity and cGMP as compared with aspirin. Platelet NOS activity and cGMP were lower in CHD subjects pre-randomization compared with healthy subjects both pre-randomization and post-aspirin. We conclude that chronic aspirin treatment suppresses β-AR-stimulated but not basal platelet NO synthesis, as previously described, whereas chronic clopidogrel treatment suppresses both, with resultant functional consequences. Moreover, CHD may itself be associated with decreased platelet NO biosynthesis. 相似文献
52.
53.
54.
Fabrizia Veronesi Lucio Nisoli Manuela Diaferia Roberto Falcini Emanuele Ficola Daniela Piergili Fioretti 《Parasitology research》2013,112(6):2137-2142
A blind, randomised, controlled, multicentric field trial was conducted to assess the influence of a metaphylactic treatment with an oral solution of toltrazuril on some reproductive parameters of Italian Fresian heifers during the first 18–20 months of life. For this goal 40 calves were selected from two dairy farms and randomly divided into two homogeneous groups: MTol, treated with toltrazuril and NegC, left untreated. The calves were clinically and coprologically examined over the entire study period. The body condition scores, the body weights and the age at the first service were recorded and compared between the two groups, in addition to some other reproductive parameters including number of pregnancies, average service per pregnancy, conception rate, conception rate at first service and post first service conception rate. The analysis of the results showed that the metaphylactic treatment with toltrazuril influenced positively the average age of the first service (MTol 461.4 days versus NegC 485.45 days), the overall conception rate (MTol 95 % versus NegC 85 %), the success at first (MTol 60 % versus NegC 45 %) and second (MTol 75 % versus NegC 45 %) services and, consequently, the mean number of services to be carried out for each animal (MTol 1.4?±?0.6 versus NegC 1.6?±?0.79). Furthermore, the results confirmed that toltrazuril treatment, applied in accordance with the epidemiological aspects of each farm, is highly efficacious in persistent reduction of oocyst excretions with particular reference to Eimeria zuernii, Eimeria bovis, considered to be mainly responsible for clinical coccidiosis. 相似文献
55.
Paola Stefanelli Antonino Bella Giorgio Fedele Serena Pancheri Pasqualina Leone Paola Vacca Arianna Neri Anna Carannante Cecilia Fazio Eleonora Benedetti Stefano Fiore Concetta Fabiani Maurizio Simmaco Iolanda Santino Maria Grazia Zuccali Giancarlo Bizzarri Rosa Magnoni Pier Paolo Benetollo Antonio Ferro 《Clinical microbiology and infection》2021,27(4):633.e1-633.e7
ObjectivesA seroprevalence study of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was conducted in a high-incidence area located in northeastern Italy.MethodsAll citizens above 10 years of age resident in five municipalities of the Autonomous Province of Trento, with the highest incidence of coronavirus disease 2019 (COVID-19) cases, were invited to participate in the study. Among 6098 participants, 6075 sera and a standardized questionnaire administered face-to-face were collected between 5 May and 15 May 2020 and examined. Symptomatic individuals and their family contacts were tested by RT-PCR. Anti-SARS-CoV-2 antibodies were detected using an Abbott SARS-CoV-2 IgG assay, which was performed on the Abbott Architect i2000SR automated analyser. Seroprevalence was calculated as the proportion of positive results among the total number tested. A multivariable logistic regression model was performed to assess the relationship between seropositive versus seronegative individuals for a set of explanatory variables.ResultsA total of 1402 participants were positive for IgG antibodies against SARS-CoV-2, with a prevalence of 23.1% (1402/6075). The highest prevalence was found in the age class 40–49 years. Overall, 34.4% (2096/6098) of the participants reported at least one symptom. The ratio between reported cases identified by molecular test and those with seropositive results was 1:3, with a maximum ratio of about 1:7 in the age group <20 years and a minimum around 1:1 in those >70 years old. The infection fatality rate was 2.5% (35/1402). Among the symptoms, anosmia and ageusia were strongly associated with seropositivity.ConclusionsThe estimated seroprevalence of 23% was three-fold higher than the number of cases reported in the COVID-19 Integrated Surveillance data in the study area. This may be explained in part by a relatively high number of individuals presenting mild or no illness, especially those of younger age, and people who did not seek medical care or testing, but who may contribute to virus transmission in the community. 相似文献
56.
Francisco Ferro de Beça Cátia Rasteiro Alda Correia Susy Costa Isabel Amendoeira 《Annals of diagnostic pathology》2013,17(5):434-436
Core-needle biopsy (CNB) of breast lesions can be classified into 5 categories according to lesion type and associated risk of malignancy. B3 category (lesion of uncertain malignant potential) constitutes a challenging problem in clinical decision, with most ending in excisional biopsy. Therefore, the aim of this study was to establish the incidence of malignancy on excision biopsy of B3 lesions and assess if subclassification (in B3a and B3b categories) according to the presence of atypia in otherwise B3 lesions better predicts malignancy on excision. Forty-eight cases with diagnosis of B3 lesion on CNB and matched surgical excision specimen were included to evaluate the positive predictive value (PPV) and odds for malignancy in CNB. All cases were further subclassified into B3a and B3b categories. B3 category lesions had an overall PPV for malignancy of 12.5% and significant low odds of malignancy of 0.14. When subclassified, B3b (lesions with atypia) demonstrated a higher PPV for malignancy (36.36%) with a nonsignificant odds. Inversely, B3a (lesions without atypia) demonstrated a PPV for malignancy of only 5.41% and a significant low odds of malignancy of only 0.06. The described low rate of malignancy in some of B3 lesions additionally reinforces the practice of avoiding surgical excision in selected patients and provides data that additionally support B3 lesion subclassification according to the presence of atypia. Subclassification of B3 category can further refine the current classification of associated risk of malignancy with possible implications in clinical management. 相似文献
57.
58.
Dario Leosco Valentina Parisi Teresa Pellegrino Gennaro Pagano Grazia Daniela Femminella Agnese Bevilacqua Stefania Paolillo Roberto Formisano Gaetana Ferro Claudio de Lucia Maria Prastaro Pasquale Perrone Filardi Alberto Cuocolo Giuseppe Rengo Nicola Ferrara 《European journal of nuclear medicine and molecular imaging》2015,42(10):1601-1611
59.
Angela Bononi Keisuke Goto Guntulu Ak Yoshie Yoshikawa Mitsuru Emi Sandra Pastorino Lorenzo Carparelli Angelica Ferro Masaki Nasu Jin-Hee Kim Joelle S. Suarez Ronghui Xu Mika Tanji Yasutaka Takinishi Michael Minaai Flavia Novelli Ian Pagano Giovanni Gaudino Harvey I. Pass Joanna Groden Joseph J. Grzymski Muzaffer Metintas Muhittin Akarsu Betsy Morrow Raffit Hassan Haining Yang Michele Carbone 《Proceedings of the National Academy of Sciences of the United States of America》2020,117(52):33466
Rare biallelic BLM gene mutations cause Bloom syndrome. Whether BLM heterozygous germline mutations (BLM+/−) cause human cancer remains unclear. We sequenced the germline DNA of 155 mesothelioma patients (33 familial and 122 sporadic). We found 2 deleterious germline BLM+/− mutations within 2 of 33 families with multiple cases of mesothelioma, one from Turkey (c.569_570del; p.R191Kfs*4) and one from the United States (c.968A>G; p.K323R). Some of the relatives who inherited these mutations developed mesothelioma, while none with nonmutated BLM were affected. Furthermore, among 122 patients with sporadic mesothelioma treated at the US National Cancer Institute, 5 carried pathogenic germline BLM+/− mutations. Therefore, 7 of 155 apparently unrelated mesothelioma patients carried BLM+/− mutations, significantly higher (P = 6.7E-10) than the expected frequency in a general, unrelated population from the gnomAD database, and 2 of 7 carried the same missense pathogenic mutation c.968A>G (P = 0.0017 given a 0.00039 allele frequency). Experiments in primary mesothelial cells from Blm+/− mice and in primary human mesothelial cells in which we silenced BLM revealed that reduced BLM levels promote genomic instability while protecting from cell death and promoted TNF-α release. Blm+/− mice injected intraperitoneally with asbestos had higher levels of proinflammatory M1 macrophages and of TNF-α, IL-1β, IL-3, IL-10, and IL-12 in the peritoneal lavage, findings linked to asbestos carcinogenesis. Blm+/− mice exposed to asbestos had a significantly shorter survival and higher incidence of mesothelioma compared to controls. We propose that germline BLM+/− mutations increase the susceptibility to asbestos carcinogenesis, enhancing the risk of developing mesothelioma.In the United States, the incidence rate of mesothelioma varies between fewer than one case per 100,000 persons in states with no asbestos industry to two to three cases per 100,000 persons in states with an asbestos industry (1, 2). Asbestos causes DNA damage and apoptosis (3) and promotes a chronic inflammatory reaction that supports the emergence of malignant cells (4). Fortunately, only a small fraction of exposed individuals develop mesothelioma; for example, 4.6% of deaths in miners who worked in asbestos mines for over 10 y were caused by mesothelioma (1). Therefore, multiple cases of mesothelioma in the same family are rare and suggest genetic predisposition (5). In 2001, we discovered that susceptibility to mesothelioma was transmitted in a Mendelian fashion across multiple generations in some Turkish families exposed to the carcinogenic fiber erionite, pointing to gene × environment interaction (G×E) as the cause (6). In 2011, we discovered that carriers of heterozygous germline BRCA1-associated protein–1 (BAP1) mutations (BAP1+/−) developed mesothelioma and uveal melanoma (5), findings expanded and confirmed by us and by multiple research teams (reviewed in refs. 1, 7, 8). Moreover, heterozygous germline Bap1 mutations (Bap1+/−) significantly increased susceptibility to asbestos-induced mesothelioma in mice (9, 10), evidence of G×E. Reduced BAP1 levels impair DNA repair (11) as well as different forms of cell death (3, 12) and induce metabolic alterations (13–15) that together favor cancer development and growth.Recent studies revealed that mesothelioma may also develop among carriers of germline mutations of additional tumor-suppressor genes that cause well-defined cancer syndromes, including MLH1 and MLH3 (Lynch syndrome), TP53 (Li–Fraumeni syndrome), and BRCA1-2 (Breast and Ovarian Cancer syndrome) (16, 17). When all germline mutations are combined, it has been estimated that about 12% of mesotheliomas occur in carriers of heterozygous germline mutations of BAP1, the most frequent mutation among patients with mesothelioma, or of other tumor suppressors. Some of these mutations may sensitize the host to asbestos carcinogenesis, according to a G×E scenario (17). Thus, presently, mesothelioma is considered an ideal model to study G×E in cancer (17). As part of the Healthy Nevada Project (HNP), we are studying G×E in northern Nevada, a region with an unusually high risk of exposure to carcinogenic minerals and arsenic, which may be related to the high cancer rates in this region (18). We are investigating genetic variants that may increase cancer risk upon exposure to carcinogens to implement preventive strategies.Biallelic mutations of the Bloom syndrome gene (BLM) cause Bloom syndrome, an autosomal-recessive tumor predisposition syndrome characterized by pre- and postnatal growth deficiency, photosensitivity, type 2 diabetes, and greatly increased risk of developing various types of cancers. BLM is a RecQ helicase enzyme that modulates DNA replication and repair of DNA damage by homologous recombination (19). In patients affected by Bloom syndrome, the absence of the BLM protein causes chromosomal instability, increased number of sister chromatid exchanges, and increased numbers of micronuclei (20–22). In addition, BLM is required for p53-mediated apoptosis (23), a process critical to eliminate cells that have accumulated DNA damage. Impaired DNA repair together with altered apoptosis resulted in increased cancer incidence (17, 24). Of course, inactivating germline BLM heterozygous (BLM+/−) mutations are much more common than biallelic BLM (BLM−/−) mutations, with an estimated frequency in the general population of 1 in 900 based on data from the Exome Aggregation Consortium (25). BLM+/− mutation carriers do not show an obvious phenotype; however, some studies have suggested that carriers of these mutations may have an increased cancer risk (17, 24). Mice carrying Blm+/− mutations are prone to develop a higher rate of malignancies in the presence of contributing factors, such as concurrent heterozygous mutations of the adenomatous polyposis coli (Apc) gene, or upon infection with murine leukemia virus (26). However, in studies in which Blm+/− mice were crossed with tuberous sclerosis 1-deficient (Tsc1+/−) mice that are predisposed to renal cystadenomas and carcinomas, Wilson et al. found that Tsc1+/− Blm+/− mice did not show significantly more renal cell carcinomas compared with Tsc1+/− BlmWT mice (27). In humans, a large study involving 1,244 patients with colon cancer and 1,839 controls of Ashkenazi Jewish ancestry, in which BLM+/− frequency is as high as 1 in 100 individuals (28), suggested that carriers of germline BLM+/− mutations might have a twofold increase in colorectal cancer (CRC) (29). A smaller study did not confirm these results, but reported a trend of increasing incidence of adenomas—premalignant lesions—among BLM+/− mutation carriers (30). In addition, BLM+/− mutations were found overrepresented among early-onset (<45 y old) CRC patients (25). Other studies associated BLM+/− mutations to an increased risk of breast (31, 32) and prostate cancer (33), but the low power of these studies hampered definite conclusions. In summary, it appears possible that BLM+/− mutations may increase cancer risk in the presence of contributing factors. 相似文献
60.
All‐on‐4® Treatment Concept for the Rehabilitation of the Completely Edentulous Mandible: A 7‐Year Clinical and 5‐Year Radiographic Retrospective Case Series with Risk Assessment for Implant Failure and Marginal Bone Level
下载免费PDF全文
![点击此处可从《Clinical implant dentistry and related research》网站下载免费的PDF全文](/ch/ext_images/free.gif)